Business
Advicenne Announces the Publication in Orphanet Journal of Rare Diseases of the Long-term European Study Results of dRTA Treatment Using ADV7103
PARIS, August 26, 2025--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces the publication in Orphanet Journal of Rare Disease (OJRD) of the long-term results of the pivotal study of ADV7103 in the treatment of distal renal tubular acidosis (dRTA).
About this update from Advicenne Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"This extensive clinical dataset serves ADV7103 registration dossier in the United States of America, expected to be submitted in Q4 2025","length":136,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":136,"olType":false},{"type":"text","content":"PARIS, August 26, 2025--(BUSINESS WIRE)--Regulatory News:","length":57,"tagName":"p"},{"type":"text","content":"Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces the publication in Orphanet Journal of Rare Disease (OJRD) of the long-term results of the pivotal study of ADV7103 in the treatment of distal renal tubular acidosis (dRTA).","length":385,"tagName":"p"},{"type":"text","content":"This European study conducted over more than six years in patients with dRTA, provides long-term clinical follow-up data on this rare disease and contributes to a better understanding of the natural history of patients affected by this rare disease.","length":249,"tagName":"p"},{"type":"text","content":"The publication is available here.","length":34,"tagName":"p"},{"type":"text","content":"These clinical results form the core of the clinical part of the registration dossier for ADV7103 in the United States, which is expected to be submitted in Q4 2025.","length":165,"tagName":"p"},{"type":"text","content":"* *","length":3,"tagName":"p","attribs":{}},{"type":"text","content":"*","length":1,"tagName":"p","attribs":{}},{"type":"text","content":"About AdvicenneAdvicenne (Euronext Growth Paris ALDVI - FR0013296746) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022.","length":615,"tagName":"p"},{"type":"text","content":"For additional information, see: https://advicenne.com/.","length":56,"tagName":"p"},{"typ...